

effective vaccines and therapeutic antibodies, providing a critical solution to a significant global health challenge.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

#### Potential Commercial Applications

- This MSP1-focused technology has the potential to transform malaria treatment and prevention worldwide, offering more effective vaccines and therapeutic antibodies for use in clinical settings, public health programs, and potentially in regions with high malaria prevalence.

#### Competitive Advantages

- This technology offers highly immunogenic and stable MSP1-based vaccine candidates and monoclonal antibodies, with superior efficacy, cost-effectiveness, and ease of production compared to current alternatives.

#### Development Stage

##### Pre-Clinical

*Inventors:* Niraj Tolia, Ph.D., Thayne Dickey, Ph.D., Palak Patel, Ph.D., Kazuotoyo Miura, Ph.D., Carole Long, Ph.D., all of NIAID.

*Publications:* Patel, Palak N et al. "Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion." *Nature communications* vol. 13, 1 5888. 6 Oct. 2022, doi:10.1038/s41467-022-33336-3.

*Intellectual Property:* HHS Reference No. E-154-2022-0-US-01, US Provisional Application No. 63/369,909, filed on July 29, 2022; HHS Reference No. E-154-2022-0-PC-01, PCT Application No. PCT/US2023/070926, filed on July 25, 2023.

*Licensing Contact:* To license this technology, please contact Peter Tung at 240-669-5483 or [peter.tung@nih.gov](mailto:peter.tung@nih.gov), and reference E-154-2022.

*Collaborative Research Opportunity:* The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Peter Tung at 240-669-5483 or [peter.tung@nih.gov](mailto:peter.tung@nih.gov).

Dated: March 14, 2024.

**Surekha Vathyam,**

*Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2024-05881 Filed 3-19-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Council of Councils.

The meeting will be held as a virtual meeting and will be open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: <https://videocast.nih.gov/>.

*Name of Committee:* Council of Councils.

*Date:* April 05, 2024.

*Time:* 01:00 p.m. to 02:30 p.m.

*Agenda:* Welcome and Opening Remarks; Announcements; Primary Care Research Network; Proposed Council of Councils Working Group on AIM-AHEAD.

*Place:* National Institutes of Health, Building 1, 1 Center Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Franziska Grieder, D.V.M., Ph.D., Executive Secretary, Council of Councils, Director, Office of Research Infrastructure Programs, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, NIH, 6701 Democracy Boulevard, Room 948, Bethesda, MD 20892, [GriederF@mail.nih.gov](mailto:GriederF@mail.nih.gov), 301-435-0744.

This notice is being published less than 15 days prior to the meeting due to scheduling difficulties.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Council of Council's home page at <http://dpcpsi.nih.gov/council/> where an agenda will be posted before the meeting date.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired

Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: March 15, 2024.

**Lauren A. Fleck,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-05869 Filed 3-19-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, NIAMS.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Board of Scientific Counselors, NIAMS.

*Date:* April 24-25, 2024.

*Time:* April 24-25, 2024, 9:00 a.m. to 12:30 p.m..

*Agenda:* To review and evaluate personnel qualifications and performance, and competence of individual investigators.

*Place:* NIH Bethesda Main Campus, Building 10, 12S233 (NIAMS 12th floor conference room), Bethesda, MD (Hybrid meeting).

*Contact Person:* John J. O'Shea, MD, Ph.D., Scientific Director, Intramural Research Program, National Institute of Arthritis & Musculoskeletal and Skin Diseases, Building 10, Room 9N228, Bethesda, MD 20892, (301) 496-2612, [osheaj@arb.niams.nih.gov](mailto:osheaj@arb.niams.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS)

Dated: March 14, 2024.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2024-05824 Filed 3-19-24; 8:45 am]

**BILLING CODE 4140-01-P**